Liposomal recombinant human superoxide-dismutase for the treatment of peyronie's disease
US6312720A · kind A · utility
31Cited by
7References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1999 |
| Grant date | Nov 6, 2001 |
| Priority date | — |
| Expiry date | Jun 7, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q19/004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Superoxide dismutase (SOD), preferably rhSOD, is used in liposomes, optionally mixed with hyaluronic acid and/or at least one physiologically acceptable carrier, and other optional additives, to prepare a pharmaceutical composition useful against increased concentrations of superoxide radicals and/or the damage caused thereby. The compositions are administered topically, preferably as gels or ointments, to prevent and/or heal human fibrotic tissue degeneration diseases, in particular induratio penis plastica (Peyronie's Disease).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.